The effect of empagliflozin on heart failure and renal outcomes by baseline diabetes status: an analysis of the EMPEROR-Reduced trial

Watch the discussion between Professors Andrew Coats and Stefan Anker surrounding the analysis of cardiovascular and renal outcomes by baseline diabetes status from the EMPEROR-Reduced Phase III trial. This study looks at the association between empagliflozin and improved cardiovascular outcomes in heart failure patients with reduced ejection fraction (HFrEF), with and without diabetes.

Topic

Part of the EMPOWER program (exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions), the EMPEROR-Reduced trial is a phase III randomised, double-blind trial that aims to evaluate the efficacy and safety of empagliflozin compared with placebo in 3,730 patients with chronic heart failure with HFrEF, with and without diabetes mellitus (DM). This 30-minute, interactive journal club will explore the efficacy and safety of empagliflozin on heart failure and renal events across the range of Hb1Ac levels in heart failure patients with HFrEF from the results of the EMPEROR-Reduced trial.

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in heart failure management or cardio-renal-metabolic conditions.

Learning objectives

• Recall the efficacy and safety of empagliflozin on cardiac and renal outcomes in patients with HFrEF, without and without DM2
• Describe why empagliflozin has a salutary effect on cardiac and renal outcomes independent of glycaemic status and how this compares to other SGLT2 inhibitors, such as dapagliflozin
• Explain the clinical implications of treating heart failure patients with and without DM2

Accreditation

The effect of empagliflozin on heart failure and renal outcomes by baseline diabetes status: an analysis of the EMPEROR-Reduced trial’ – live webinar’ has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) CPD credit(s).